Cipla Ltd
NSE:CIPLA
Intrinsic Value
Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. [ Read More ]
The intrinsic value of one CIPLA stock under the Base Case scenario is 1 082.53 INR. Compared to the current market price of 1 386.65 INR, Cipla Ltd is Overvalued by 22%.
Valuation Backtest
Cipla Ltd
Run backtest to discover the historical profit from buying and selling CIPLA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cipla Ltd
Current Assets | 190.1B |
Cash & Short-Term Investments | 71.7B |
Receivables | 48.5B |
Other Current Assets | 69.8B |
Non-Current Assets | 123.7B |
Long-Term Investments | 9.8B |
PP&E | 56.1B |
Intangibles | 44.6B |
Other Non-Current Assets | 13.1B |
Current Liabilities | 56.5B |
Accounts Payable | 26.8B |
Other Current Liabilities | 29.7B |
Non-Current Liabilities | 9B |
Long-Term Debt | 2.2B |
Other Non-Current Liabilities | 6.9B |
Earnings Waterfall
Cipla Ltd
Revenue
|
253.5B
INR
|
Cost of Revenue
|
-88.3B
INR
|
Gross Profit
|
165.2B
INR
|
Operating Expenses
|
-114.8B
INR
|
Operating Income
|
50.4B
INR
|
Other Expenses
|
-13.3B
INR
|
Net Income
|
37.1B
INR
|
Free Cash Flow Analysis
Cipla Ltd
CIPLA Profitability Score
Profitability Due Diligence
Cipla Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Cipla Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
CIPLA Solvency Score
Solvency Due Diligence
Cipla Ltd's solvency score is 98/100. The higher the solvency score, the more solvent the company is.
Score
Cipla Ltd's solvency score is 98/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CIPLA Price Targets Summary
Cipla Ltd
According to Wall Street analysts, the average 1-year price target for CIPLA is 1 438.14 INR with a low forecast of 1 025.15 INR and a high forecast of 1 837.5 INR.
Shareholder Return
CIPLA Price
Cipla Ltd
Average Annual Return | 22.27% |
Standard Deviation of Annual Returns | 37.08% |
Max Drawdown | -35% |
Market Capitalization | 1.1T INR |
Shares Outstanding | 807 395 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. The company is headquartered in Mumbai, Maharashtra and currently employs 21,891 full-time employees. The Company’s segments include Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The firm's geographical segments include India, the United States, South Africa and Rest of the World. The firm has its network of manufacturing, trading and other incidental operations in India and International markets. The firm has approximately 46 manufacturing sites.
Contact
IPO
Employees
Officers
The intrinsic value of one CIPLA stock under the Base Case scenario is 1 082.53 INR.
Compared to the current market price of 1 386.65 INR, Cipla Ltd is Overvalued by 22%.